The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products
An intuitive monitor featuring a patient-tailored approach is now in clinical use in select centres in U.S. and Europe
The new unit will be built with INEOS’ latest process technology and aims to substantially improve the sustainability of our supply to our customers and reduce our environmental impact
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
The Blockchain-based solution was awarded the 2021 Bionow Technical Service Award
The new facility is scheduled to start operation in the first half of 2024
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It also secures US $ 10 million for US launch and commercialization
Subscribe To Our Newsletter & Stay Updated
